newsfilter
← Latest News
GlobeNewswire·

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug